Abstract. This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that. Risk of febrile neutropenia (FN) should be systematically assessed (in consultation with infectious disease specialists as needed), including. Febrile neutropenia (FN) is a serious complication of cancer chemotherapy that The Infectious Diseases Society of America (IDSA), National.
|Country:||Bosnia & Herzegovina|
|Published (Last):||13 March 2013|
|PDF File Size:||10.50 Mb|
|ePub File Size:||1.40 Mb|
|Price:||Free* [*Free Regsitration Required]|
This guideline provides a general approach to the management of patients with cancer who have neutropenia and present with fever, and it gives special attention to antimicrobial management.
Risk assessment and treatment of low-risk patients with febrile neutropenia.
Guidelines in the Management of Febrile Neutropenia for Clinical Practice
Clinical variations among patients mandate that clinical judgment play a critical role in identifying which patients require antibiotics during the risk period of neutropenia, even if those patients do not meet these specific definitions. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors.
Nonetheless, the Panel recommends that every patient with fever and neutropenia receive empirical antibiotic therapy urgently ie, within 2 h after presentation, because infection may progress rapidly in these patients. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern.
Monotherapy for fever and neutropenia in cancer patients: Public Health Patient Stories. Most patients will have no infectious etiology documented.
Guidelines in the Management of Febrile Neutropenia for Clinical Practice
Detection of bloodstream infections in adults: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients neutrkpenia fever and neutropenia. Because staphylococci rebrile microaerophilic viridans group streptococci are encountered among fluoroquinolone prophylaxis recipients, some authorities have advocated adding a gram-positive agent to the prophylactic regimen [ ].
These agents should be considered for specific clinical indications, including suspected catheter-related infection, skin and soft-tissue infection, pneumonia, or hemodynamic instability. However, neutropenia is not a predisposition to reactivation of either virus; thus, prevention strategies for these 2 herpes viruses are not discussed in this document [ ].
Pneumonia neuttropenia neutropenic patients should generally be treated as a health care—acquired infection according to recent guidelines from the American Thoracic Society [ ]. Hemodynamically unstable neutropenic patients with persistent fever without a clear source should have their antimicrobial regimen broadened to ensure adequate coverage for drug-resistant gram-negative and gram-positive organisms, as well as for anaerobes.
Culture of urine samples is indicated if signs or symptoms of urinary tract infection exist, a urinary catheter is in place, or the findings of urinalysis are abnormal. Despite the obvious advantages of oral therapy, including reduced cost, lack of need for indwelling IV access, decreased febrild, and improved patient acceptance [ 35 ], few studies have assessed the feasibility of managing patients solely in the outpatient setting. Antibiotic treatment may therefore extend beyond resolution of fever and neutropenia.
Fever may be the lone sign of invasive fungal infection; therefore, to prevent late initiation of treatment, empirical antifungal therapy for persistent or recrudescent neutropenic fever neuutropenia has been the standard approach for many decades [ 2].
Less common organisms include Bacillus speciesCorynebacterium JK, enterococci including Idsrapidly growing mycobacteria, and non-fermentative gram-negative bacilli [ ]. Initial management of fever and neutropenia.
IDSA GUIDELINES Bundle (free trial) – Fever and Neutropenia
Ndutropenia are insufficient to recommend a specific empirical antifungal agent for a patient already receiving anti-mold prophylaxis, but switching to a different class of anti-mold antifungal that is given intravenously should be considered B-III.
Although voriconazole is used for prophylaxis in some centers, no large randomized studies involving patients with AML or MDS have been performed to date. All members of the Panel participated in the preparation and review of the draft guideline. Immunosuppressed patients and those who have been hospitalized or received antibiotics within the preceding 90 days are considered to be among those at high risk for developing pneumonia with multidrug-resistant pathogens.
In general, the use of oral febrilw may be considered only for patients who fulfill clear criteria for being at neugropenia for complications during neutropenia, as defined above [ 4244—45 ].
In view of the widespread presence of MRSA in both hospital and community settings, the Panel recognizes that there may be an increasing epidemiologic rationale for employing vancomycin as a part of the empirical regimen. The current data are not sufficient to recommend routine use of these tests to guide decisions about antimicrobial use. The Infectious Febriel Society of America Fever and Neutropenia Guideline aims to provide a rational summation of these evolving algorithms. This suggestion is based on the evidence that fungal infection breakthroughs may be related to inadequate serum levels of voriconazole or posaconazole when they are given orally [ — ].
Culture specimens from other sites of suspected infection should be obtained as clinically indicated A-III.
Changing epidemiology of infections in patients with neutropenia and cancer: Serious infections due neutropenai S. Increasingly, drug-resistant gram-negative bacterial species are responsible for infections in febrile neutropenic patients.
The goal of initial empirical antibiotic therapy is to prevent serious morbidity and mortality due to bacterial pathogens, until the results of blood cultures are available to guide more-precise antibiotic choices.
Plants and dried or fresh flowers should febirle be allowed in the rooms of hospitalized neutropenic patients B-III.
For those beutropenia who have initiated IV antibiotic therapy, neutopenia step down to the oral regimen of gebrile plus amoxicillin-clavulanate is recommended for low-risk patients when they become afebrile after 3 days of treatment, are clinically stable, and have no discernable infection or positive culture results [ ].
Risk assessment may determine the type of empirical antibiotic therapy oral vs intravenous [IV]venue of treatment inpatient vs outpatientand duration of antibiotic therapy A-II. Despite the predominance of gram-positive organisms as the cause of bacteremia during fever and neutropenia, randomized studies comparing empirical regimens with and without vancomycin as part of the initial empirical regimen have shown no significant reductions in either the duration of fever or overall mortality [ 606293— ].
Patients with neutropenia, other than HSCT recipients, do not need to be placed into a single-patient room. The addition of polymyxin-colistin or tigecycline to the early treatment is appropriate if the presence of Klebsiella pneumoniae carbapenemase-producing bacteria is suspected.
Email Address Password Forgot Password?
The Panel members are listed as authors of this document. Vancomycin-resistant enterococcal infections in bone marrow transplant recipients. For management of most patients, the Panel recommends involvement of an infectious diseases specialist knowledgeable about infections of the immunocompromised host. The bacterial pathogens that cause most bloodstream infections in the setting of neutropenia are listed in Table 1.
There is limited value in sending a stool specimen for bacterial pathogen cultures or for ova and parasite examination for most patients treated in US hospitals unless there has been recent travel to or residence in areas of endemicity. Furthermore, the selection of patients who may benefit the most from antimicrobial prophylaxis see Section VI is based upon these criteria for being at high risk, which are derived from clinical trials [ 20—41 ].
Prophylaxis should be given until recovery of the white blood cell count or resolution of mucositis, whichever occurs later.